Pure Global
NCT05871021

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

A Phase IIa, Open-label, Multicenter Study of Radiochemotherapy With Isotoxic Dose Escalation and Protective VEGF Inhibition Using Bevacizumab in the Treatment of Patients With First Diagnosis of IDH Wild-type, MGMT Unmethylated Glioblastoma
Ludwig-Maximilians - University of Munich·Phase 2·ClinicalTrials.gov·radiationNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Glioblastoma
Drug/Device/Intervention
Dose escalation of radiation dose beyond the therapeutic standard
Study type
Interventional
Intervention type
radiation
Sponsor & location
Primary sponsor
Ludwig-Maximilians - University of Munich
Timeline & enrollment
Phase
Phase 2
Start date
Oct 01, 2023
End date
Jan 01, 2027
Enrollment
146 participants
Primary outcome

OS

Summary

Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive
 treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor,
 and dose escalation seems to be warranted, but causes more toxicity. To address this, the
 multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation
 isotoxically. The goal is improved survival without significantly increasing side effects.
 The study uses a simultaneous integrated boost with a total dose of 75 Gy in 2.5 Gy per
 fraction.

ICD-10 classifications
Malignant neoplasm of brainMalignant neoplasm: Brain, unspecifiedMesotheliomaMalignant neoplasm: Brain stemMalignant neoplasm: Overlapping lesion of brain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05871021
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05871021 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ludwig-Maximilians - University of Munich and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 146 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.